RxDoctor Payments Data

Robert Masters, MD

Cardiovascular Disease · Laguna Hills, CANPI 1871685214

Payments from drug & device makers

$16,385in general payments, 2019–2025

Across 613 payments — averaging $26.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$3K
  • AOP Health US, LLC$1K
  • Novartis$977
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$858
  • Amgen$705
  • Boehringer Ingelheim$599
  • plus $9K from 44 others

What the payments were for

  • Food & beverage$15,97898%
  • Education$4062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,385 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$325,263
Medicare patients
617
Services billed
3,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$153,125
XareltoRivaroxaban110$110,071
EntrestoSacubitril/Valsartan55$63,538
Repatha SureclickEvolocumab40$54,411
BrilintaTicagrelor33$31,019
JardianceEmpagliflozin13$20,634
FarxigaDapagliflozin Propanediol19$18,908
EdarbyclorAzilsartan Med/Chlorthalidone33$13,349
OzempicSemaglutide14$12,456
Amiodarone Hcl195$5,817
Nebivolol Hcl33$2,645
Atorvastatin Calcium239$2,392
Digoxin91$2,314
Metoprolol Succinate131$1,882
Rosuvastatin Calcium104$1,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$203$153,125141 claims
Johnson & JohnsonXarelto$407$110,071110 claims
NovartisEntresto$977$63,53855 claims
AstraZenecaBrilinta, Farxiga$408$49,92752 claims
Boehringer IngelheimJardiance$599$20,63413 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$64$13,34933 claims
Novo NordiskOzempic$462$12,45614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →